Depomed to Develop an Extended-Release Formulation of Compound
Depomed announced an agreement with Boehringer Ingelheim Pharmaceuticals, (BIPI) to develop a controlled-release dosage form of an undisclosed pharmaceutical compound. The collaboration entails Depomed applying its Gastric Retention (GR) technology to develop an extended, controlled-release formulation of one of BIPI's pharmaceutical compounds. Under the agreement, BIPI will reimburse Depomed for costs and out of pocket expenses associated with the program.
Yahoo News (http://biz.yahoo.com/bw/050428/285212.html?.v=1)